Complement Tests

PDF iconKidney Disease Testing Requisition Form (Effective beginning January 3, 2017)

Uncontrolled complement activity drives many diseases including two ultra-rare renal diseases, Dense Deposit Disease (DDD) and C3 glomerulonephritis (C3GN), both examples of C3 glomerulopathy (C3G), and atypical hemolytic uremic syndrome (aHUS), an ultra-rare type of thrombotic microangiopathy (TMA). Complement assays are useful to:

  • Define levels of complement proteins and their breakdown products
  • Provide a biomarker profile of an individual’s complement activity
  • Identify acquired drivers of disease, such as autoantibodies to C3 convertase called C3 nephritic factors or C3Nefs
  • Predict likely response to anti-complement therapies for specific diseases
  • Provide a metric to follow a patient’s clinical course